BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25970717)

  • 21. Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
    Lawrenson K; Pakzamir E; Liu B; Lee JM; Delgado MK; Duncan K; Gayther SA; Liu S; Roman L; Mhawech-Fauceglia P
    PLoS One; 2015; 10(7):e0130909. PubMed ID: 26132201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium.
    Lax SF
    Pathology; 2007 Feb; 39(1):46-54. PubMed ID: 17365822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular pathology of endometrial carcinoma.
    Matias-Guiu X; Prat J
    Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
    Han G; Soslow RA; Wethington S; Levine DA; Bogomolniy F; Clement PB; Köbel M; Gilks B; DeLair D
    Int J Gynecol Pathol; 2015 Jul; 34(4):323-33. PubMed ID: 25851704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted mutation analysis of endometrial clear cell carcinoma.
    Hoang LN; McConechy MK; Meng B; McIntyre JB; Ewanowich C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2015 Apr; 66(5):664-74. PubMed ID: 25308272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update.
    Horn LC; Meinel A; Handzel R; Einenkel J
    Ann Diagn Pathol; 2007 Aug; 11(4):297-311. PubMed ID: 17630117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
    Lax SF
    Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New features in the 2014 WHO classification of uterine neoplasms].
    Lax SF
    Pathologe; 2016 Nov; 37(6):500-511. PubMed ID: 27738815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Histological and molecular classification of endometrial carcinoma and therapeutical implications].
    Genestie C; Leary A; Devouassoux M; Auguste A
    Bull Cancer; 2017 Dec; 104(12):1001-1012. PubMed ID: 29031505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular carcinogenesis of ovarian carcinoma].
    Diebold J
    Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
    Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
    Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma?
    Bae HS; Kim H; Young Kwon S; Kim KR; Song JY; Kim I
    Int J Gynecol Pathol; 2015 Jan; 34(1):74-84. PubMed ID: 25473756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endometrial carcinoma: pathology and genetics.
    Prat J; Gallardo A; Cuatrecasas M; Catasús L
    Pathology; 2007 Feb; 39(1):72-87. PubMed ID: 17365824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endometrial carcinoma: molecular alterations involved in tumor development and progression.
    Yeramian A; Moreno-Bueno G; Dolcet X; Catasus L; Abal M; Colas E; Reventos J; Palacios J; Prat J; Matias-Guiu X
    Oncogene; 2013 Jan; 32(4):403-13. PubMed ID: 22430211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences.
    Gatius S; Cuevas D; Fernández C; Roman-Canal B; Adamoli V; Piulats JM; Eritja N; Martin-Satue M; Moreno-Bueno G; Matias-Guiu X
    Pathobiology; 2018; 85(1-2):35-40. PubMed ID: 28614814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival.
    Mahdi Z; Abdulfatah E; Pardeshi V; Hassan O; Schultz D; Morris R; Cote ML; Elshaikh MA; Bandyopadhyay S; Ali-Fehmi R
    Int J Gynecol Pathol; 2017 Sep; 36(5):405-411. PubMed ID: 28277313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rare Subtype of Endometrial Cancer: Undifferentiated/Dedifferentiated Endometrial Carcinoma, from Genetic Aspects to Clinical Practice.
    Tung HJ; Wu RC; Lin CY; Lai CH
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.